Daclizumab, marketed as Zinbryta, was approved for the treatment of relapsing-remitting multiple sclerosis (MS) in the USA and Europe in summer 2016. Daclizumab has shown superior efficacy when compared to placebo and a standard treatment (AVONEX®, interferon beta-1a) and is
Continue …Daclizumab – Manipulating the immune system in unexpected ways
After I tweeted about my recent post about Immunium, another Twitter user made me aware of iCancer. Why? – Because the clinical trial financed through the iCancer fundraising campaign used the Ad5PTDf35-adenovirus vector which Immunicum
Continue …iCancer – The first step into the future of funding clinical trials?
I thought I kick off the year with an article about Immunicum, a Swedish company I stumbled across a week or so ago. As an immunologist by training I have a soft spot for companies
Continue …Immunicum – Scalable Personalised Cancer Immunotherapy